Stimulants, Caffeine, Tobacco and Vaping
Drugs and Society
Learning objectives for this lesson:
- Describe cocaine, amphetamine and methamphetamine, their forms and routes of use, and their legal status in Canada as of 2026.
- Explain how transporter blockers such as cocaine and releasers such as amphetamine raise dopamine and noradrenaline, and why fast routes such as smoking increase reinforcement.
- Summarize the evidence on the cardiovascular and psychiatric harms of stimulants, including the dose-related risk of psychosis with methamphetamine use, and interpret dated Canadian data on stimulant-involved deaths.
- Explain how prescription stimulants for ADHD work, how formulation reduces their potential for non-medical use, and what the evidence, including dated Canadian survey data, shows about their non-medical use by students.
- Explain how caffeine acts on adenosine receptors, and calculate the caffeine remaining after a dose from its half-life.
- Explain how nicotine acts on nicotinic receptors and why dependence on smoked nicotine develops quickly and persists.
- Explain why the products of combustion cause most smoking-related disease while nicotine sustains smoking, using Doll and Hill’s 1950 study and the British Doctors Study, and summarize dated Canadian data on smoking and tobacco-attributable deaths.
- Compare e-cigarettes, heated tobacco products and nicotine pouches on relative risk, effectiveness for stopping smoking and youth uptake, using evidence of differing certainty and dated Canadian data on vaping.
- Explain the logic of tobacco harm reduction and weigh conflicting evidence and positions in the debate, applying them to a Canadian policy decision about nicotine products.
This course was developed by Dr. Kiffer G. Card.
Cocaine, Amphetamine and Methamphetamine
Content note
This section discusses deaths from the unregulated drug supply, psychosis and violence associated with stimulant use. Support is available in Canada through the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the National Overdose Response Service for people who use drugs alone (1-888-688-6677), and the Hope for Wellness Help Line for Indigenous people (1-855-242-3310).
Introduction
A stimulant is a drug that increases activity in the brain and in the sympathetic nervous system, which prepares the body for effort by raising heart rate, blood pressure and alertness. This lesson covers stimulants ranging from caffeine, the most widely used psychoactive drug in the world, to cocaine and methamphetamine, along with prescribed medicines for attention-deficit/hyperactivity disorder (ADHD) and the nicotine in tobacco and vaping products.
This first section concerns cocaine and the amphetamines, the two families of stimulants with the largest illegal markets. Farrell and colleagues (2019), in a Lancet review of global stimulant use, reported estimates from the United Nations Office on Drugs and Crime’s 2018 World Drug Report that about 18.2 million people aged 15 to 64 used cocaine and about 34.2 million used amphetamines in a year, equal to about 0.4 percent and 0.7 percent of the world’s population in that age range. In Canada, the Canadian Substance Use Survey (CSUS) found that 3 percent of respondents had used cocaine or crack in the 12 months before the 2023 survey, and that fewer than 1 percent had used amphetamines or methamphetamine (Health Canada, 2024a). Household surveys miss many people who use these drugs most heavily, a limitation Lesson 1 described, so these figures are best read as lower bounds.
The section moves from the drugs themselves (1.1) to the way they act at the synapse and why speed of delivery matters (2.1 and 2.2), the physical risks they carry (3.1), the psychosis that can follow heavy use (3.2) and their part in Canada’s toxic drug crisis (3.3).
Learning Objectives
- 1.1 Describe cocaine, amphetamine and methamphetamine, their main forms and routes of use, and their legal status in Canada as of 2026.
- 2.1 Explain the difference between a transporter blocker such as cocaine and a releaser such as amphetamine, using the dopamine transporter as the example.
- 2.2 Explain why rapid routes such as smoking and injection increase the reinforcing effects and risks of stimulants.
- 3.1 Summarize the main cardiovascular, physical and mortality risks of stimulant use reported in systematic reviews.
- 3.2 Summarize the evidence on stimulant psychosis and interpret the dose-response findings of McKetin and colleagues (2013) on methamphetamine use and psychotic symptoms.
- 3.3 Describe the place of stimulants in Canada’s unregulated drug supply using dated data from the BC Coroners Service and the Public Health Agency of Canada.
1.1 Two Families of Stimulants
Cocaine and the amphetamines both increase noradrenaline and dopamine activity and sympathetic arousal (Farrell et al., 2019). They come from different sources, and their chemistry shapes how long each lasts and how each is used.
1.1.1 Cocaine: From Coca Leaf to Powder and Crack
Cocaine is a natural product of the leaves of the coca shrub (Erythroxylum coca), grown mainly in Bolivia, Colombia and Peru (Farrell et al., 2019); Lesson 2 described the history of coca use. Cocaine is extracted from the leaves and sold in two chemical forms (Farrell et al., 2019; European Union Drugs Agency [EUDA], n.d.-a). Cocaine hydrochloride is a white powder that dissolves in water, so it can be snorted or injected. Cocaine freebase, including the form sold as crack, is the smokable form. Swallowed cocaine loses much of its activity because enzymes in the gut break it down. Cocaine also has a legitimate medical use: solutions of cocaine hydrochloride serve as a topical anaesthetic in some surgery of the eye, ear, nose and throat (EUDA, n.d.-a).
Cocaine is short-acting. Its plasma half-life, the time taken for the concentration in the blood to fall by half (a term Lesson 3 introduced), is about 0.7 to 1.5 hours (EUDA, n.d.-a). When alcohol is taken with cocaine, the liver produces an additional active compound, cocaethylene.
1.1.2 Amphetamine and Methamphetamine: Synthetic Stimulants
Amphetamine and methamphetamine are synthetic drugs of the phenethylamine family, usually grouped together as amphetamines (Farrell et al., 2019). In 1927 the chemist Gordon Alles synthesized amphetamine while looking for a cheaper substitute for ephedrine, and it was marketed in 1935 under the trade name Benzedrine for narcolepsy, mild depression and other conditions (Heal et al., 2013). Section 2 returns to this medical history. Methamphetamine is closely related to amphetamine and more potent; its crystalline hydrochloride form is known as “ice” or crystal, and it is also sold as powder and tablets (EUDA, n.d.-b). Methamphetamine lasts much longer than cocaine, with a plasma half-life of about nine hours (EUDA, n.d.-b).
Table 6.1 compares the two drugs that dominate illegal stimulant markets in Canada. Read the half-life row with Lesson 3 in mind: a drug cleared within an hour or two wears off quickly, while a drug with a nine-hour half-life keeps acting long after it is taken.
Table 6.1. Cocaine and methamphetamine compared on source, forms, routes, half-life and legal status in Canada.
| Feature | Cocaine | Methamphetamine |
|---|---|---|
| Source | Extracted from coca leaves | Synthetic (made from chemical precursors) |
| Main forms | Hydrochloride powder; freebase or crack | Crystal (“ice”), powder, tablets |
| Common routes | Powder snorted or injected; crack smoked | Smoked, injected, snorted or swallowed |
| Plasma half-life | About 0.7 to 1.5 hours | About 9 hours |
| Medical use | Topical anaesthetic in some surgery | Occasional therapeutic use for narcolepsy and ADHD in some countries |
| Status in Canada (2026) | Schedule I, Controlled Drugs and Substances Act | Schedule I, Controlled Drugs and Substances Act |
Sources: EUDA (n.d.-a, n.d.-b); Farrell et al. (2019); Controlled Drugs and Substances Act (consolidation current to 21 September 2026).
Under Canada’s Controlled Drugs and Substances Act, coca and cocaine, methamphetamine and the amphetamines are all listed in Schedule I, which carries the highest maximum penalty for possession (seven years when prosecuted as an indictable offence) and a maximum of life imprisonment for trafficking. Lesson 11 explains how schedules work. The next part turns to what both families of drugs do inside the brain.
2.1 How Stimulants Act at the Synapse
Lesson 3 introduced receptors, the proteins that drugs bind to in order to produce their effects. Cocaine and the amphetamines act mainly on a different kind of protein, the transporter, and interfere with it in two ways.
2.1.1 What a Transporter Normally Does
Dopamine, noradrenaline and serotonin are chemical messengers called monoamines. When a nerve cell releases dopamine into the synapse, the narrow gap between two nerve cells, the dopamine binds to receptors on the receiving cell and passes on a signal. The signal is kept brief because a protein in the wall of the sending cell, the dopamine transporter, pumps dopamine back into the sending cell so it can be stored and used again. Separate transporters do the same job for noradrenaline and serotonin. Inside the sending cell, a second pump called the vesicular monoamine transporter 2 (VMAT2) loads the recycled dopamine into small storage sacs called vesicles (Heal et al., 2013).
2.1.2 Blockers and Releasers
Cocaine is a transporter blocker. It binds to the dopamine transporter and blocks the removal of dopamine from the synapse, so dopamine builds up and the receiving cells get an amplified signal (National Institute on Drug Abuse [NIDA], n.d.). Methylphenidate, a medicine for ADHD discussed in Section 2, also inhibits the dopamine and noradrenaline transporters (Faraone, 2018). 3-D Model 6.1 shows the measured atomic structure of the human dopamine transporter with cocaine lodged in the central site where dopamine itself binds.
Amphetamine and methamphetamine are releasers. Amphetamine resembles the monoamines closely enough that the transporters carry it into the sending cell. Once inside, it displaces dopamine from the cell’s internal pool and, because it also acts on VMAT2, it stops dopamine from being loaded into vesicles. The result is that the transporter runs in reverse and pumps dopamine out of the cell into the synapse, a process called reverse transport (Heal et al., 2013; Faraone, 2018). Sulzer and colleagues (2005) describe the same mechanisms for the substituted amphetamines as a group, including methamphetamine. In the animal experiments reviewed by Heal and colleagues (2013), amphetamine raised dopamine in the striatum to more than 50 times its baseline level, five to ten times the maximum produced by classic reuptake inhibitors such as the antidepressant bupropion.
Figure 6.1 shows the three situations side by side: normal recycling, a blocker and a releaser.
3-D Model 6.2 animates the same three situations at a dopamine synapse, with a toggle that compares the synapse with and without each drug, and its last two steps show how nicotine (Section 3) and caffeine (Section 2) change dopamine signalling by other routes.
Interactive 6.1 asks you to sort eight substances by how they act. Five are covered later in this lesson, so the feedback explains each one.
Choose the main way each substance raises activity in the brain, then select Check my answers.
2.2 Why Speed of Delivery Matters
Lesson 3 showed that the route of administration controls how fast a drug reaches the brain and that faster delivery strengthens a drug’s reinforcing effects. Stimulants are a clear example. Heal and colleagues (2013) explain that euphoria and reinforcement follow rapid, large increases of dopamine in the brain’s reward areas, which leads some people to move from swallowing tablets to snorting, smoking or injecting. Cocaine enters the brain very quickly; the peak effects of methamphetamine came 10 to 15 minutes later in brain imaging studies. Lesson 8 develops the neurobiology of reward.
Smoking has become the most common way of using drugs among people who die from the unregulated drug supply in British Columbia. In a release dated 2 December 2025, which reported data up to October 2025, the BC Coroners Service stated that smoking was the most common mode of consumption among deaths in 2025 (65 percent), followed by snorting (11 percent), injection (10 percent) and oral use (5 percent) (BC Coroners Service, 2025). These figures are preliminary.
Whether a stimulant blocks or reverses the transporter, the result is more dopamine and noradrenaline outside the nerve cells. The effects on the heart and blood vessels follow from the noradrenaline side of that action, which the next part describes.
3.1 Cardiovascular and Physical Risks
Noradrenaline is the main messenger of the sympathetic nervous system, so cocaine and the amphetamines both produce a fast heart rate (tachycardia) and high blood pressure (hypertension) (EUDA, n.d.-a, n.d.-b). Systematic reviews link these drugs with a range of physical harms.
Farrell and colleagues (2019) reported consistent evidence that stimulant use increases cardiovascular disease and death. The acute harms include acute coronary syndrome and heart attack (myocardial infarction), tearing of the wall of the aorta (aortic dissection) and dangerous heart rhythms (arrhythmias); the chronic harms include coronary artery disease and damage to the heart muscle (cardiomyopathy). Stroke is also more common. Heavy drinking, which often accompanies stimulant use, increases the risk of damage to the heart and of violent behaviour. Across the systematic reviews they summarized, people who used amphetamines died at 6.83 times the rate expected in the general population, and people who used cocaine at 6.13 times the expected rate, measures known as standardized mortality ratios. Suicide, overdose, injuries and cardiovascular disease all contribute to this excess mortality. The flip cards below summarize the main physical risks.
These physical harms help explain why people who use stimulants heavily die earlier than their peers. Stimulants also affect the mind, and the most serious psychiatric effect, psychosis, is the subject of the next part.
3.2 Stimulant Psychosis
Psychosis is a state in which a person loses contact with shared reality, usually through hallucinations (perceiving things that are not present) or delusions (fixed false beliefs). Clinicians have recognized for decades that heavy stimulant use can produce psychotic symptoms; in 1966, Connell, of the Institute of Psychiatry, described a group of people using large amounts of amphetamine who had become paranoid (Heal et al., 2013). The research question has been whether the drug causes these symptoms or whether people who already had a tendency toward psychosis were simply more likely to use stimulants.
3.2.1 What Systematic Reviews Show
Farrell and colleagues (2019) describe stimulant-related psychotic symptoms as typically transient. They tend to follow chronic heavy use and feature paranoia (intense suspiciousness) and hallucinations that are heard or seen. The reviews they cite report that people who use amphetamines had about double the odds of psychotic symptoms, a figure from a meta-analysis by McKetin and colleagues (2019) in which most studies were cross-sectional and whose authors called for better population-level studies, so this evidence is still developing. Estimates of the prevalence of psychotic symptoms among people dependent on cocaine ranged from 7 to 75 percent. Among people who use methamphetamine, psychosis was most consistently linked with how often and how much they used, the severity of dependence and the use of other drugs. Symptoms usually ease once a person reduces or stops use, but in a minority they persist or return, and stimulants can bring on or worsen episodes in people with schizophrenia.
3.2.2 A Within-person Study of Dose and Psychosis
McKetin and colleagues (2013) designed a study to separate the effect of the drug from the characteristics of the people who use it. They followed 278 people in Sydney and Brisbane, Australia, who met criteria for methamphetamine dependence and had no lifetime diagnosis of schizophrenia or mania. Each participant was assessed in four separate one-month periods, and the analysis compared each person with themselves, asking whether psychotic symptoms were more likely in the months when that person used methamphetamine. Because each person serves as their own comparison, stable characteristics such as genes or childhood experiences cannot explain the difference between months. Table 6.2 shows the main results, expressed as odds ratios: an odds ratio of 5 means that the odds of psychotic symptoms were about five times as high in that condition as in months without use.
Table 6.2. Odds of clinically significant psychotic symptoms in months of methamphetamine use compared with months of no use among 278 people with methamphetamine dependence (McKetin et al., 2013).
| Pattern in the past month | Odds ratio (95% confidence interval) |
|---|---|
| Any methamphetamine use compared with none | 5.3 (3.4 to 8.3) |
| Use on 1 to 15 days compared with none | 4.0 (2.5 to 6.5) |
| Use on 16 or more days compared with none | 11.2 (5.9 to 21.1) |
| Frequent cannabis use (16 or more days) | 2.0 (1.1 to 3.5) |
| Frequent alcohol use (16 or more days) | 2.1 (1.1 to 4.2) |
The results show a dose-response relationship: the more days of use in a month, the higher the odds of psychotic symptoms. A dose-response pattern within the same people strengthens the case that the drug itself contributes to the symptoms, although other things that change during heavy-use months, such as lost sleep, may also play a part. Farrell and colleagues (2019) found only a small amount of evidence on antipsychotic medicines for stimulant psychosis specifically. HSCI 214 develops mental illness and its treatment. Try it 6.1 asks you to read Table 6.2 closely.
Use Table 6.2 to answer three questions. How do the odds of psychotic symptoms compare between months with 1 to 15 days of use and months with 16 or more days? Why does comparing each person with themselves make a pre-existing tendency toward psychosis an unlikely explanation? What does the wide confidence interval for heavy use (5.9 to 21.1) tell you about the precision of that estimate?
Psychosis, cardiovascular disease and infection all affect people who use stimulants. In Canada, many recent deaths have involved stimulants together with the toxic opioid supply, which the final part of this section examines.
3.3 Stimulants in Canada’s Unregulated Drug Supply
Lesson 5 described how illicitly manufactured fentanyl made Canada’s unregulated opioid supply toxic, and why agencies call the resulting deaths drug toxicity deaths or overdose deaths. Stimulants are part of the same crisis, because many people who die from the unregulated supply have both opioids and stimulants in their bodies. Case 6.1 summarizes dated, preliminary data from 2025 and 2026.
British Columbia declared a public health emergency over drug toxicity deaths on 14 April 2016, and the BC Coroners Service publishes data on these deaths in regular releases. In a release dated 2 December 2025, which reported data up to October 2025, it stated that among people who died in 2025 and underwent expedited toxicology testing, fentanyl was found in 69 percent, fluorofentanyl in 53 percent, cocaine in 53 percent and methamphetamine in 52 percent (BC Coroners Service, 2025). In October 2025, more than 90 percent of suspected unregulated drug deaths that underwent expedited testing detected a stimulant, compared with about 80 percent in October 2024. A later release, dated 14 October 2026, reported that among deaths in 2026 that underwent expedited testing, fluorofentanyl was the substance detected most often (68 percent), followed by cocaine (56 percent), methamphetamine (53 percent) and fentanyl (50 percent) (BC Coroners Service, 2026). All of these figures are preliminary and may change as investigations conclude.
National surveillance shows the same overlap. The Public Health Agency of Canada reported, in an update dated 22 September 2026, that 62 percent of apparent opioid toxicity deaths from January to March 2026 also involved a stimulant, and that 40 percent of stimulant-related poisoning hospitalizations in the same period also involved an opioid (Public Health Agency of Canada, 2026). Both figures are preliminary.
Consider what these data can and cannot tell you. Detection of a stimulant shows that the drug was present at death; it does not by itself show that the stimulant caused the death or whether the person intended to take it.
The overlap has several sources. Some people use both drugs on purpose, and Farrell and colleagues (2019) describe growing concern in the United States and Canada about interactions between cocaine, methamphetamine and fentanyl. Others may take a drug they did not intend to because the unregulated supply is unpredictable. Treatment options are also limited: Farrell and colleagues (2019) reported that no effective medicines to reduce stimulant use were available when they wrote, and that psychosocial treatments had a weak overall effect, with the exception of contingency management, which gives tangible rewards for verified abstinence. The box below shows where the series develops these responses.
Where this course leaves stimulant treatment and harm reduction
This lesson holds the pharmacology of stimulants for the series. Treatment for stimulant use disorder, including contingency management, harm reduction services such as drug checking and supervised consumption, and the measurement of drug toxicity deaths are developed in HSCI 402 (Substance Use, Addiction and Public Health). Infections among people who use drugs are developed in HSCI 212, and Lesson 11 of this course examines how drug laws and enforcement shape the supply.
Summary and Transition
Cocaine and the amphetamines raise dopamine and noradrenaline by blocking or reversing the transporters that normally clear these messengers from the synapse. Fast routes such as smoking and injection intensify their reinforcing effects, and their effects on the cardiovascular system and the mind account for much of their harm. In British Columbia, more than 90 percent of suspected unregulated drug deaths that underwent expedited toxicology testing in October 2025 had a stimulant detected, according to preliminary data. Stimulants are also prescribed as medicines and consumed every day in coffee and tea. Section 2 examines prescription stimulants for ADHD, their non-medical use by students, and caffeine, using the same pharmacology to explain why these drugs differ so much in risk.
Key Takeaways
- 1.1 Cocaine is extracted from coca leaves and sold as a hydrochloride powder that is snorted or injected, or as freebase (crack) that is smoked; it is short-acting, with a plasma half-life of about 0.7 to 1.5 hours. Amphetamine and methamphetamine are synthetic stimulants, and methamphetamine’s half-life of about 9 hours keeps it acting long after a dose. Coca, cocaine, methamphetamine and the amphetamines are all in Schedule I of the Controlled Drugs and Substances Act as of 2026.
- 2.1 Cocaine is a transporter blocker: it binds to the dopamine transporter and stops dopamine from being cleared from the synapse, so dopamine builds up. Amphetamine and methamphetamine are releasers that are carried into the sending cell, act on VMAT2 and make the transporter run in reverse, pumping dopamine out. Either way, more dopamine and noradrenaline remain outside the nerve cells.
- 2.2 Euphoria and reinforcement follow rapid, large increases of dopamine in the brain’s reward areas, so faster routes such as smoking and injection strengthen a stimulant’s reinforcing effects and lead some people to move from swallowing tablets to snorting, smoking or injecting. Preliminary BC Coroners Service data show that smoking was the most common mode of consumption among unregulated drug deaths in 2025 (65 percent).
- 3.1 Through noradrenaline, stimulants raise heart rate and blood pressure, and systematic reviews link them with heart attack, aortic dissection, arrhythmias, cardiomyopathy and stroke. People who used amphetamines died at 6.83 times, and people who used cocaine at 6.13 times, the rate expected in the general population, with suicide, overdose, injuries and cardiovascular disease contributing to the excess.
- 3.2 Stimulant psychosis is typically transient and follows chronic heavy use, with paranoia and hallucinations. In McKetin and colleagues’ (2013) within-person study, the odds of psychotic symptoms were 4.0 times as high in months with 1 to 15 days of methamphetamine use and 11.2 times as high in months with 16 or more days, a dose-response pattern that strengthens the case that the drug itself contributes.
- 3.3 Stimulants are part of Canada’s toxic drug crisis. In preliminary BC Coroners Service data for 2025, cocaine was detected in 53 percent and methamphetamine in 52 percent of deaths that underwent expedited toxicology testing, and nationally 62 percent of apparent opioid toxicity deaths from January to March 2026 also involved a stimulant. Detection shows that a drug was present at death, not that it caused the death or that the person intended to take it.
Reflection
Case 6.1 reports that among unregulated drug deaths in British Columbia in 2025 that underwent expedited toxicology testing, fentanyl was detected in 69 percent, cocaine in 53 percent and methamphetamine in 52 percent, and that smoking was the most common mode of consumption (65 percent). Using what you learned about transporter blockers and releasers, routes of administration, and the cardiovascular and psychiatric risks of stimulants, explain two reasons why stimulants deserve attention in a crisis often described as an opioid crisis. Then state one limitation of using toxicology detection figures to draw conclusions about the role of stimulants.
The first reason is that stimulants carry their own serious risks. Cocaine blocks the dopamine and noradrenaline transporters and methamphetamine reverses them, and the extra noradrenaline raises heart rate and blood pressure. Farrell and colleagues (2019) link stimulant use with heart attack, aortic dissection, arrhythmias, stroke and standardized mortality ratios above six. Heavy methamphetamine use also raises the odds of psychotic symptoms in a dose-dependent way (McKetin et al., 2013). A person who uses both opioids and stimulants faces strain on the heart, the lungs and the brain at once.
The second reason is the route. Smoking was the most common mode of use in 2025, and smoking delivers stimulants to the brain within seconds, which strengthens reinforcement and encourages repeated use, especially for cocaine, whose half-life is under two hours. Responses designed around injection and opioids alone will miss much of this pattern.
The main limitation is that detection shows only that a drug was present at death. It does not show that the stimulant caused the death, how much was taken, or whether the person intended to take it, since the unregulated supply is unpredictable. The figures are also preliminary and come from deaths that underwent expedited testing.
Minimum 20 characters required.
Question 1: Which statement best describes how amphetamine raises dopamine in the synapse?
Question 2: Table 6.1 gives a plasma half-life of about 0.7 to 1.5 hours for cocaine and about 9 hours for methamphetamine. Which conclusion follows from these figures?
Question 3: In McKetin and colleagues’ (2013) study, what was the main advantage of comparing each participant’s months of methamphetamine use with that same person’s months without use?
Question 4: According to the BC Coroners Service release of 2 December 2025, which statement about 2025 deaths that underwent expedited toxicology testing is accurate?
Prescription Stimulants and Caffeine
Introduction
The stimulants in Section 1 are illegal in Canada except in narrow medical uses. Many people meet stimulants in two other ways: as medicines prescribed for attention-deficit/hyperactivity disorder (ADHD), and as the caffeine in coffee, tea and soft drinks. Both cases show that the risks of a drug depend on its dose, speed of delivery, formulation and setting of use as well as on the molecule, a point Lesson 3 made about drug, set and setting.
This section follows amphetamine from its early marketing as a medicine to the ADHD medicines of today and the formulations that slow their delivery (4.1 and 4.2), examines the non-medical use of these medicines by students (4.3), and then turns to caffeine, the most widely consumed psychoactive drug in the world (5.1 and 5.2), including a calculator that applies the half-life concept from Lesson 3.
Learning Objectives
- 4.1 Describe the history of amphetamine as a medicine and the stimulant medicines used for ADHD today, with their mechanisms and legal status in Canada.
- 4.2 Explain how slow-release and prodrug formulations such as lisdexamfetamine reduce the reinforcing effects of a stimulant.
- 4.3 Summarize the evidence on how common non-medical use of prescription stimulants is among students, why students use them and whether they improve cognition in healthy people.
- 5.1 Explain how caffeine acts on adenosine receptors and why its reinforcing effects are weaker than those of cocaine or amphetamine.
- 5.2 Calculate the amount of caffeine remaining after a dose using the half-life formula, and explain how smoking and pregnancy change caffeine’s half-life.
4.1 Stimulant Medicines for ADHD
ADHD is a condition, usually first recognized in childhood, marked by persistent patterns of inattention, hyperactivity or impulsivity that interfere with daily functioning. Stimulant medicines are first-line medical treatments for it (Faraone, 2018). Their history, summarized in the box below, explains both their usefulness and the concern about their misuse.
Amphetamine’s early history as a medicine
Heal and colleagues (2013) trace amphetamine from a laboratory curiosity to a controlled drug. After Gordon Alles synthesized it in 1927, the company Smith, Kline and French marketed it in 1935 as Benzedrine, for narcolepsy, mild depression and a range of other disorders, and in 1937 it began selling the more potent d-isomer as Dexedrine. Reports that Benzedrine improved scores on intelligence tests led academics, students and medical professionals to use it to improve concentration and intellectual performance in the 1930s. During the Second World War, an estimated 150 million Benzedrine tablets were supplied to British and American service personnel. The addictive potential of amphetamine was largely dismissed at the time. Concern grew after reports such as Connell’s 1966 description of people using large amounts of amphetamine who had become paranoid, and after prescribed amphetamine was diverted to young people.
This history shows that the use of stimulants to improve study and work performance is close to a century old. Writing in 2013, Heal and colleagues (2013) described the therapeutic use of amphetamine as largely restricted to ADHD and narcolepsy.
Faraone (2018), in a review written for physicians, describes amphetamines and methylphenidate as first-line medicines for ADHD. The main effect of both is to increase the activity of dopamine and noradrenaline in the brain, which affects executive functions (planning, organizing and controlling behaviour) and attention. The two drugs work in the different ways described in Section 1. Methylphenidate mainly inhibits the dopamine and noradrenaline transporters, which makes it a blocker. Amphetamine also inhibits the transporters, and in addition interferes with VMAT2 and drives monoamines out of the cell by reverse transport, which makes it a releaser (Faraone, 2018). Atomoxetine, a non-stimulant alternative, selectively inhibits the noradrenaline transporter and has little effect on dopamine in the brain’s reward areas (Heal et al., 2013). Table 6.3 compares these medicines.
Table 6.3. Medicines used for ADHD compared by drug class and main mechanism of action.
| Medicine | Class | Main mechanism |
|---|---|---|
| Methylphenidate | Stimulant | Inhibits dopamine and noradrenaline transporters (blocker) |
| Amphetamine salts and dextroamphetamine | Stimulant | Releases dopamine and noradrenaline by reverse transport; also acts on VMAT2 |
| Lisdexamfetamine | Stimulant (prodrug) | Converted to d-amphetamine in red blood cells, then acts as a releaser |
| Atomoxetine | Non-stimulant | Selectively inhibits the noradrenaline transporter |
Sources: Faraone (2018); Heal et al. (2013).
3-D Model 6.3 shows where in the brain the dopamine and noradrenaline transporters that these medicines act on are concentrated, using maps made with positron emission tomography (PET), a scanning method that measures where an injected radioactive tracer binds, and its last two steps turn to the nicotinic receptors that Section 3 discusses.
Under the Controlled Drugs and Substances Act, the amphetamines are in Schedule I and methylphenidate is in Schedule III, which carries a lower maximum penalty for possession (three years when prosecuted as an indictable offence) than Schedule I (Controlled Drugs and Substances Act, consolidation current to 21 September 2026).
4.2 Why Speed and Formulation Matter
Medical and non-medical stimulant use differ in dose and in speed. Heal and colleagues (2013) note that people who use stimulants non-medically generally take doses several times higher than therapeutic doses and may move to faster routes. Taken by mouth at therapeutic doses, amphetamine reaches the brain more slowly than snorted or smoked stimulants, which makes it less rewarding. Drug makers have used this principle. Lisdexamfetamine is a prodrug, an inactive compound that the body converts into an active drug. It consists of d-amphetamine bound to the amino acid L-lysine; after absorption, red blood cells slowly split the two apart. This rate-limited conversion produces a more gradual rise in brain amphetamine levels, which reduces its pleasurable effects and the risk of diversion (Heal et al., 2013). Extended-release capsules and tablets that resist tampering follow the same logic.
Formulation lowers the risk of misuse without removing it. Prescribed stimulants are still shared and sold, especially among students, which is the subject of the next part.
4.3 Non-medical Use of Prescription Stimulants by Students
Non-medical use of a prescription drug means taking it without a prescription, or in a way other than prescribed, for example at a higher dose or to study longer. Research on students has asked how common this is, why students do it and whether it helps.
The four tabs below summarize the evidence on prevalence, motives and sources, effects on cognition, and Canadian data.
Benson and colleagues (2015) combined studies of college students, most of them in the United States, in a meta-analysis, a statistical method that pools the results of many studies. They estimated that 17 percent of college students had used stimulant medication non-medically (95 percent confidence interval 13 to 23 percent). The authors warned that studies defined misuse in different ways and lacked validated measures, which makes the pooled estimate uncertain. A later systematic review by Faraone and colleagues (2020) found that self-reported rates in population samples ranged from 2.1 to 58.7 percent and that studies used a variety of terms for non-medical use, so estimates of how common it is vary widely.
Benson and colleagues (2015) found that students used prescription stimulants mainly for academic reasons, and that the most common source was friends or classmates with prescriptions. Students who used them non-medically had more ADHD symptoms, more alcohol-related problems and more cannabis use than students who did not, and membership in fraternities and sororities was also associated with use.
Ilieva, Hook and Farah (2015) pooled 48 studies with 1,409 healthy participants who received methylphenidate or amphetamine. They found small improvements in inhibitory control (the ability to stop an automatic response) and short-term memory, and a medium effect on delayed memory, but evidence of publication bias weakened the memory findings. They concluded that the effect on healthy cognition is probably modest overall, and that healthy users may take stimulants to increase energy and motivation more than to improve thinking. A later series of meta-analyses by Roberts and colleagues (2020) found small effects of methylphenidate on some aspects of thinking in healthy adults and no effects of d-amphetamine. Research on these questions is still developing.
In the Canadian Substance Use Survey 2023, 5 percent of respondents had used a prescription stimulant in the past 12 months, and 82 percent of prescription stimulant use was for medical purposes. Past-year use was 14 percent among people aged 15 to 24, compared with 4 percent among adults aged 25 and older (Health Canada, 2024a). In the Canadian Student Alcohol and Drugs Survey (CSADS, 2023 to 2024; called the Canadian Student Tobacco, Alcohol and Drugs Survey in earlier cycles), 2 percent of students in grades 7 to 12 in nine provinces reported using ADHD medication for non-recommended purposes in the past 12 months (Health Canada, 2025a).
Read together, the reviews in the tabs suggest that non-medical use of prescription stimulants is common among students, although estimates depend on how studies define it, that the cognitive benefit for people without ADHD is small or modest, and that the risks follow from the pharmacology in Section 1. Higher doses bring the cardiovascular effects described in Section 1, and combining stimulants with heavy drinking increases the risk to the heart (Farrell et al., 2019). The most widely used stimulant is caffeine, found in everyday food and drink, and the final part of this section turns to it.
5.1 Caffeine: The Most Widely Used Psychoactive Drug
Caffeine is the most consumed psychoactive drug in the world; in the United States, 87 percent of children and adults regularly consume foods and drinks that contain it (Ferré, 2016). It is a mild stimulant compared with amphetamine and cocaine, and its everyday familiarity makes it a useful example of the concepts from Lesson 3: receptors, tolerance, withdrawal and half-life.
5.1.1 How Caffeine Works: Releasing the Adenosine Brake
Adenosine is a chemical in the brain that builds up during waking activity and acts as a natural brake on arousal. Caffeine is a non-selective competitive antagonist at two adenosine receptors, A1 and A2A (Fredholm et al., 1999, as cited in Ferré, 2016). Lesson 3 defined an antagonist as a drug that occupies a receptor without activating it. By blocking adenosine receptors, caffeine releases the brake that adenosine places on the brain’s dopamine and arousal systems (Ferré, 2016). Figure 6.2 shows this in simplified form.
Caffeine increases alertness and psychomotor activity and has mild reinforcing effects, but its reinforcing effects are weaker and its potential for problematic use is lower than those of the prototypical stimulants (Ferré, 2016). The difference follows from the mechanism. Cocaine and amphetamine raise dopamine directly and powerfully at the transporter, while caffeine works indirectly, by removing a brake that adenosine places on dopamine signalling. Ferré (2016) also notes that children and adolescents are more sensitive to caffeine’s stimulant effects.
5.1.2 Tolerance and Withdrawal
Regular caffeine use produces tolerance, and stopping produces a recognizable withdrawal syndrome. The American Psychiatric Association accepted caffeine withdrawal as a clinical diagnosis in 2013, with symptoms that include headache, marked fatigue or drowsiness, low or irritable mood, difficulty concentrating and flu-like symptoms (Ferré, 2016). Ferré (2016) notes that part of the improvement in alertness that regular users feel after a dose could reflect the relief of withdrawal symptoms, an example of negative reinforcement that Lesson 8 develops.
5.1.3 Caffeine in Combination with Other Drugs
Caffeine is usually considered on its own, but it also appears alongside other drugs. Ferré (2016) describes two concerns. Energy drinks are sometimes consumed with alcohol, and caffeine is a common adulterant in illegal drug preparations, particularly cocaine, amphetamine derivatives and synthetic cathinones, where animal studies show it can increase the stimulant and toxic effects of those drugs. Lesson 7 describes synthetic cathinones and other new psychoactive substances.
5.2 Caffeine Intake and Half-life
How much caffeine remains in the body at a given time depends on how much was consumed and how quickly the liver clears it.
5.2.1 How Much Caffeine People Consume
Health Canada publishes average caffeine content for common foods and drinks and recommends maximum daily intakes. Table 6.4 lists a selection.
Table 6.4. Average caffeine content of selected drinks and foods and Health Canada’s recommended maximum daily intakes (Health Canada, 2025b).
| Product | Serving | Caffeine |
|---|---|---|
| Coffee, brewed | 237 mL (8 oz) | 135 mg |
| Coffee, filter drip | 237 mL | 179 mg |
| Coffee, instant | 237 mL | 76 to 106 mg |
| Coffee, decaffeinated | 237 mL | 3 mg |
| Tea, black or green, brewed | 237 mL | 30 to 50 mg |
| Cola, regular | 355 mL (12 oz) | 36 to 46 mg |
| Milk chocolate | 28 g (1 oz) | 7 mg |
| Recommended maximum daily intake: 400 mg for healthy adults; 300 mg for people who are pregnant, breastfeeding or planning to become pregnant; 2.5 mg per kilogram of body weight for children and adolescents. | ||
5.2.2 Caffeine’s Half-life and the Factors That Change It
Caffeine is rapidly and completely absorbed from the gut and is broken down almost entirely in the liver. The liver enzyme CYP1A2 carries out the main step, which accounts for about 80 to 90 percent of caffeine’s initial breakdown (Grzegorzewski et al., 2021). Lesson 3 explained that liver enzyme activity varies between people and can be changed by other substances. Caffeine is a clear example. Smoking tobacco speeds up caffeine’s clearance and shortens its half-life, while oral contraceptives have the opposite effect (Grzegorzewski et al., 2021). The European Food Safety Authority (EFSA, 2015) gives the average half-life of caffeine in healthy adults as about 4 hours, with a range of 2 to 8 hours, and notes that it varies with age, body weight, pregnancy, medication and liver health. In a presentation to an EFSA meeting the same year, Gundert-Remy (2015) reported that the half-life lengthens progressively during pregnancy, up to about 16 hours.
Lesson 3 introduced the half-life formula. Because each half-life removes half of what remains, the amount of caffeine left after a single dose can be calculated as shown in the formula box below, and Worked Example 6.1 applies the formula to an afternoon coffee.
Worked Example 6.1: Coffee in the afternoon
A person drinks one 237 mL cup of brewed coffee (135 mg of caffeine, Table 6.4) at 3 p.m. and goes to bed at 11 p.m., 8 hours later. Assume a hypothetical half-life of 5 hours, a value inside the adult range of 2 to 8 hours.
Number of half-lives = 8 ÷ 5 = 1.6. Fraction remaining = (½)1.6 = 0.330. Amount remaining = 135 mg × 0.330 = 44.5 mg at bedtime, about one third of the dose.
With a half-life of 3 hours, the amount at bedtime would be 21.3 mg. With a half-life of 16 hours, which can occur late in pregnancy, it would be 95.5 mg, more than two thirds of the dose. The calculation assumes the dose is absorbed completely and quickly, which is close to true for caffeine.
Use Calculator 6.1 to repeat Worked Example 6.1 and to explore how the dose, the time since the dose and the half-life change the result.
These calculations matter for sleep. Drake and colleagues (2013) gave participants 400 mg of caffeine, or a placebo, at bedtime, 3 hours before bedtime or 6 hours before bedtime, and found that all three caffeine conditions disturbed sleep compared with placebo. They concluded that caffeine taken 6 hours before bed has important disruptive effects on sleep, which supports advice to avoid substantial caffeine for at least 6 hours before bedtime. Try it 6.2 uses Calculator 6.1 to connect these findings.
Use Calculator 6.1 to answer three questions. First, select the preset based on Drake and colleagues’ dose (400 mg taken 6 hours before bed, with a hypothetical half-life of 5 hours): how much caffeine remains at bedtime? Second, keeping the dose at 135 mg and the half-life at 5 hours, find roughly how many hours must pass before less than 10 mg remains (you should find about 19 hours). Third, compare a half-life of 3 hours with one of 8 hours for the same coffee: how would smoking, which shortens caffeine’s half-life, change the answer to the second question?
Summary and Transition
Prescription stimulants and caffeine share the stimulant pharmacology of Section 1 and differ from cocaine and methamphetamine in dose, speed and mechanism. ADHD medicines are taken by mouth at therapeutic doses, and formulations such as lisdexamfetamine slow their delivery to the brain. Non-medical use by students is common, and meta-analyses published in 2015 and 2020 suggest small or modest benefits for healthy users. Caffeine works indirectly by blocking adenosine receptors, produces tolerance and withdrawal, and is cleared at a rate that depends on liver enzymes, smoking and pregnancy. Section 3 turns to nicotine, a stimulant that is mild at the receptor yet strongly addictive, and to the smoked tobacco product that makes it the leading cause of substance-related death in Canada.
Key Takeaways
- 4.1 Amphetamine was synthesized by Gordon Alles in 1927, marketed as Benzedrine in 1935 and used by students to improve concentration, and concern about its misuse grew after reports of paranoia among people using large amounts. Faraone (2018) describes amphetamines and methylphenidate as first-line ADHD medicines: methylphenidate blocks the dopamine and noradrenaline transporters, amphetamine releases these messengers by reverse transport, and atomoxetine is a non-stimulant option. As of 2026, the amphetamines are in Schedule I and methylphenidate in Schedule III of the Controlled Drugs and Substances Act.
- 4.2 Taken by mouth at therapeutic doses, ADHD medicines reach the brain more slowly than snorted or smoked stimulants, which makes them less rewarding. Lisdexamfetamine is a prodrug that red blood cells slowly convert to d-amphetamine, producing a gradual rise in brain levels that reduces its pleasurable effects and the risk of diversion; tamper-resistant extended-release products follow the same logic. Formulation lowers the risk of misuse without removing it.
- 4.3 A meta-analysis estimated that 17 percent of college students had used stimulant medication non-medically, mainly for academic reasons and with medicines from friends or classmates, although inconsistent definitions make the estimate uncertain. In healthy people the cognitive benefit appears small or modest, with small improvements in inhibitory control and short-term memory. In Canada in 2023, 5 percent of respondents had used a prescription stimulant in the past year, most of it for medical purposes, and past-year use was 14 percent among people aged 15 to 24.
- 5.1 Caffeine is a competitive antagonist at adenosine A1 and A2A receptors, so it releases the brake that adenosine places on the brain’s dopamine and arousal systems. Because it works indirectly rather than raising dopamine directly at the transporter, its reinforcing effects are weaker than those of cocaine or amphetamine. Regular use produces tolerance and a recognized withdrawal syndrome, and caffeine added to illegal drugs can increase their stimulant and toxic effects.
- 5.2 The amount of caffeine remaining equals the dose multiplied by one half raised to the power of the hours since the dose divided by the half-life; with a half-life of 5 hours, about one third of a 135 mg afternoon coffee remains 8 hours later. The adult half-life averages about 4 hours (range 2 to 8), smoking shortens it, and it lengthens progressively during pregnancy up to about 16 hours. Caffeine taken 6 hours before bed still disturbs sleep.
Reflection
In this hypothetical scenario, a first-year student tells you that a friend with an ADHD prescription has offered them methylphenidate for long study nights, and that “it is basically strong coffee.” Using the evidence in Section 2, write a reply that (a) compares how methylphenidate and caffeine act in the brain, (b) summarizes what the meta-analysis by Ilieva and colleagues (2015), which pooled 48 studies with 1,409 healthy participants, found about cognitive benefits, (c) notes that Benson and colleagues (2015) estimated that 17 percent of college students had used prescription stimulants non-medically, mostly for academic reasons and mostly obtained from peers, and (d) mentions the legal status of methylphenidate in Canada (Schedule III of the Controlled Drugs and Substances Act).
Methylphenidate and coffee act in quite different ways. Methylphenidate inhibits the dopamine and noradrenaline transporters, so it directly raises the levels of both messengers in the brain, the same kind of action cocaine has, although at prescribed doses and taken by mouth it reaches the brain much more slowly. Caffeine works indirectly: it blocks adenosine receptors and removes a natural brake on arousal, and its reinforcing effects are weaker than those of the prototypical stimulants. Calling methylphenidate strong coffee hides that difference.
The evidence on benefits is also weaker than many students assume. Ilieva and colleagues found small improvements in inhibitory control and short-term memory in healthy people, and concluded that the overall effect on healthy cognition is probably modest; part of the appeal may be extra energy and motivation. You would be among many students who try this, since Benson and colleagues estimated that about 17 percent of college students had done so, but common use does not make it effective.
There are also risks. Higher doses raise heart rate and blood pressure, and combining stimulants with heavy drinking adds strain on the heart. Methylphenidate is in Schedule III, so possessing it without a prescription is an offence, and sharing a prescription moves a medicine out of the setting it was prescribed for.
Minimum 20 characters required.
Question 1: Why does lisdexamfetamine have lower potential for non-medical use than immediate-release d-amphetamine?
Question 2: Which finding did Benson and colleagues (2015) report in their meta-analysis of non-medical prescription stimulant use among college students?
Question 3: How does caffeine increase alertness?
Question 4: A person drinks 270 mg of caffeine at noon. Assuming a hypothetical half-life of 5 hours, about how much caffeine remains at 10 p.m.?
Nicotine, Tobacco and the Harms of Combustion
Introduction
Nicotine is the psychoactive drug in tobacco. Benowitz (2010) describes the main reasons people use it as the enhancement of mood, either directly or through the relief of withdrawal symptoms, and the improvement of mental or physical functioning. Many people who use it become dependent, and the cigarette is a highly efficient device for delivering it. The combination made smoked tobacco the largest single cause of substance-related death in Canada in 2020: Health Canada, citing the Canadian Substance Use Costs and Harms project of the Canadian Centre on Substance Use and Addiction (CCSA), reported that tobacco was responsible for nearly two in three deaths attributed to substance use that year, or 46,366 deaths (Health Canada, 2024b).
This section explains how nicotine acts in the brain (6.1) and why dependence develops quickly (6.2), then shows why burning tobacco causes most of the harm while nicotine sustains the habit (7.1) and how epidemiology helped establish that harm (7.2), and closes with tobacco use in Canada, including the distinction between commercial and traditional tobacco (7.3).
Learning Objectives
- 6.1 Explain how nicotine acts on nicotinic acetylcholine receptors, including the role of the alpha-4 beta-2 receptor and dopamine release.
- 6.2 Explain why inhaled nicotine produces dependence quickly, using the speed of delivery, the half-life of nicotine, receptor desensitization and conditioned cues.
- 7.1 Explain why the products of combustion cause most of the disease and death from smoked tobacco while nicotine sustains its use.
- 7.2 Describe the design and main findings of Doll and Hill’s 1950 case-control study and the British Doctors Study, and calculate simple proportions from their data.
- 7.3 Summarize dated Canadian data on smoking prevalence and tobacco-attributable deaths, and distinguish commercial tobacco from traditional tobacco.
6.1 How Nicotine Acts on the Brain
Lesson 3 introduced agonists, drugs that bind to a receptor and activate it. Nicotine is an agonist at a family of receptors named after it, the nicotinic acetylcholine receptors. This part explains what those receptors are and how activating them leads to reward.
6.1.1 Nicotinic Receptors
Acetylcholine is one of the body’s chemical messengers. One type of receptor for it, the nicotinic acetylcholine receptor, is an ion channel: a protein made of five subunits arranged around a pore in the cell membrane. When nicotine binds at the interface between two subunits, the channel opens and lets sodium or calcium enter the cell, which in turn triggers the release of chemical messengers (Benowitz, 2010). The brain has several types of nicotinic receptor built from different subunits. Benowitz (2010) identifies the receptor made of alpha-4 and beta-2 subunits, written α4β2, as the principal mediator of nicotine dependence. In mice, disrupting the gene for the beta-2 subunit eliminates the behavioural effects of nicotine, and reinserting the gene into the ventral tegmental area, a midbrain region that contains dopamine neurons, restores them. Another receptor type, α3β4, probably mediates nicotine’s effects on the heart and blood vessels. 3-D Model 6.4 shows the measured atomic structure of the α4β2 receptor with nicotine bound at the two sites between an alpha-4 and a beta-2 subunit, and the central pore through which sodium and calcium ions enter the cell.
6.1.2 From Receptor to Reward
Stimulating nicotinic receptors releases several messengers in the brain. Dopamine is the most important for reinforcement: nicotine activates α4β2 receptors on neurons in the ventral tegmental area, which release dopamine in a region called the nucleus accumbens (Benowitz, 2010). Nicotine also increases the release of glutamate, which promotes dopamine release, and of GABA, which inhibits it. With long-term exposure, some receptors become unresponsive while others do not, so the net balance shifts toward more excitation. Figure 6.3 traces the path from a puff to dopamine release.
The pathway in Figure 6.3 resembles the one that cocaine and amphetamine act on, which Lesson 8 develops as the brain’s reward system. The difference lies in how nicotine is delivered and how the receptors adapt, the subject of the next part.
6.2 Why Dependence Develops Quickly
Many people who smoke find it very hard to stop. Benowitz (2010) reported that 70 percent of people who smoke in the United States say they would like to quit and 40 percent stop for at least a day each year, but only about 3 percent quit successfully each year. Four features of nicotine and the cigarette help explain this.
6.2.1 Speed and Control of Delivery
Smoking is a highly efficient way to deliver a drug. After a puff, high levels of nicotine reach the brain in 10 to 20 seconds, faster than with an intravenous injection, which produces rapid reinforcement (Benowitz et al., 2009). The person who smokes can also adjust the dose puff by puff by changing the size and depth of each puff. Benowitz (2010) notes that cigarettes have been designed with additives and engineering features that enhance their addictiveness. Lesson 3’s point about route of administration applies with full force: the same molecule delivered slowly, as in a nicotine patch, has low potential for problematic use.
6.2.2 Half-life and Accumulation
The plasma half-life of nicotine averages about 2 hours (Benowitz et al., 2009). Because each cigarette adds nicotine before the last dose has cleared, nicotine accumulates over 6 to 8 hours of regular smoking and significant levels persist for 6 to 8 hours after the last cigarette, which means that a person who smokes until bedtime still has nicotine in the body through the night. The liver converts most nicotine to cotinine, mainly through the enzyme CYP2A6, and cotinine’s longer half-life of about 16 hours makes it the standard biological marker of tobacco use (Benowitz et al., 2009). People who inherit slower forms of CYP2A6 tend to smoke fewer cigarettes a day, and faster nicotine metabolism is associated with more severe withdrawal and lower success with the nicotine patch (Benowitz, 2010).
6.2.3 Desensitization, Tolerance and Withdrawal
With repeated exposure, α4β2 receptors become desensitized: they close and stop responding while nicotine is still bound. The brain compensates by making more nicotinic binding sites, a change called upregulation (Benowitz, 2010). Daily smoking keeps these receptors almost completely saturated and desensitized. During overnight abstinence, the receptors recover, and craving and withdrawal begin; the next cigarette relieves them. Benowitz (2010) concludes that people who smoke are probably attempting to avoid withdrawal when they maintain this desensitized state, and that nicotine withdrawal causes anxiety and stress, both powerful incentives to smoke again.
6.2.4 Cues, Other Smoke Constituents and Vulnerability
The accordion below summarizes three further influences on dependence.
Through repeated pairing, the taste and feel of smoke, particular places, moods and activities become linked with nicotine’s effects, and these cues alone can trigger an urge to smoke. Benowitz (2010) describes this as a form of conditioning supported by neural plasticity, changes in brain cells and their connections. Lesson 8 develops cue-triggered craving.
Constituents of cigarette smoke other than nicotine also contribute to dependence. Compounds formed in smoke inhibit monoamine oxidase, an enzyme that breaks down dopamine and other monoamines, which may increase the rewarding effects of nicotine (Benowitz, 2010).
Benowitz (2010) reports that about 80 percent of people who smoke in the United States began by age 18, and that among young people who try cigarettes, 20 to 25 percent become dependent daily smokers, usually as adults. The risk of dependence is higher when smoking begins early. Tobacco dependence is also much more common among people with mental illness or substance use disorders. Canadian data show a similar gradient: in the Canadian Substance Use Survey 2023, 20 percent of people who rated their mental health as poor or fair had smoked a cigarette in the past 30 days, compared with 10 percent of those who rated it very good or excellent (Health Canada, 2024a).
Figure 6.4 brings these ideas together in a schematic of nicotine levels across a day of smoking, compared with a nicotine patch.
Fast delivery, a short half-life that invites the next dose, receptors that signal withdrawal when nicotine falls, and cues tied to daily routines make nicotine dependence persistent. None of these features explains why smoking kills. The next part shows that the harm comes mostly from the smoke.
7.1 Combustion: Why Smoked Tobacco Is the Most Harmful Form of Nicotine Use
When tobacco burns, it produces smoke that contains many toxic compounds in addition to nicotine. Benowitz (2010) summarizes the relationship between nicotine and smoking-caused disease in two sentences: “Smoking-caused disease is a consequence of exposure to toxins in tobacco smoke. Although nicotine plays a minor role, if any, in causing smoking-induced diseases, addiction to nicotine is the proximate cause of these diseases.” In other words, nicotine keeps people smoking, and the products of combustion do most of the damage.
Health Canada states that tobacco use is a known or probable cause of more than 40 debilitating and often fatal diseases, that some chemicals in tobacco smoke are carcinogenic (cancer-causing), and that smoking can shorten life expectancy by about 10 years (Health Canada, 2023). Benowitz (2010) lists cancer, cardiovascular disease and lung disease as the major causes of death, along with infections, osteoporosis, reproductive disorders, delayed wound healing, ulcers and diabetes. The comparison with nicotine replacement therapy (NRT) shows the importance of the delivery system. Nicotine gum, patches, lozenges and inhalers deliver nicotine through the lining of the mouth or through the skin, more slowly than smoking, which gives them low potential for problematic use, while the nasal spray delivers nicotine faster, at a rate closer to smoking (Benowitz et al., 2009). These products deliver nicotine without smoke, and Section 4 asks where newer products fall between them and the cigarette.
7.2 Discovering and Confirming the Harm
Two epidemiological studies were central to establishing the harm of smoked tobacco, first a case-control study and then a cohort study that followed doctors for half a century.
7.2.1 Discovering the Harm: Doll and Hill, 1950
The evidence that smoking causes lung cancer came from epidemiology, the study of how disease is distributed in populations. Richard Doll and Austin Bradford Hill (1950) asked 20 London hospitals to notify them of patients with lung cancer between April 1948 and October 1949. Interviewers then questioned each patient with lung cancer about their smoking history, and also questioned a comparison patient of the same sex and similar age who was in hospital for a disease other than cancer. This design, which compares people with a disease (cases) and people without it (controls) on a past exposure, is called a case-control study. Table 6.5 reproduces their main comparison.
Table 6.5. Patients who did and did not smoke among patients with lung cancer and comparison patients with other diseases, London, 1948 to 1949 (Doll & Hill, 1950, Table IV).
| Group | Did not smoke | Smoked | Total |
|---|---|---|---|
| Men with lung cancer | 2 | 647 | 649 |
| Men with other diseases (controls) | 27 | 622 | 649 |
| Women with lung cancer | 19 | 41 | 60 |
| Women with other diseases (controls) | 32 | 28 | 60 |
Doll and Hill defined a smoker as a person who had smoked at least one cigarette a day for at least one year; any less consistent smoking was ignored.
Worked Example 6.2 calculates the key proportions from Table 6.5.
Worked Example 6.2: Comparing proportions in Doll and Hill’s data
The proportion of men with lung cancer who did not smoke is 2 ÷ 649 = 0.003, or 0.3 percent. The proportion among male controls is 27 ÷ 649 = 0.042, or 4.2 percent. Not smoking was about 13.5 times as common among the male controls as among the men with lung cancer (4.2 ÷ 0.3, calculated from the unrounded proportions). For women, the proportions were 19 ÷ 60 = 31.7 percent among patients with lung cancer and 32 ÷ 60 = 53.3 percent among controls.
Doll and Hill (1950) also found a dose-response gradient: among the men who smoked, 26.0 percent of those with lung cancer had recently smoked 25 or more cigarettes a day, compared with 13.5 percent of the male controls. They considered whether the association could arise because lung cancer caused people to smoke, or because a third factor caused both, and rejected these explanations because smoking began long before the disease and they could not envisage a common cause acting over 20 to 50 years. They concluded “that smoking is a factor, and an important factor, in the production of carcinoma of the lung.” Try it 6.3 asks you to work through their reasoning.
Using Table 6.5, calculate the percentage of men with lung cancer who had smoked and the percentage of male controls who had smoked. The two percentages are both high (99.7 and 95.8 percent). Explain why Doll and Hill focused on the small groups of patients who did not smoke, and why the dose-response gradient (among men who smoked, 26.0 percent of those with lung cancer compared with 13.5 percent of controls smoking 25 or more cigarettes a day) strengthened their conclusion.
7.2.2 Confirming the Harm: The British Doctors Study
A case-control study looks backward from disease to exposure. To confirm their finding, Doll and Hill began a cohort study, which follows people forward in time: in 1951 they asked British doctors about their smoking and then recorded the causes of their deaths. Doll and colleagues (2004) reported the results after 50 years of follow-up of 34,439 male doctors. Men born between 1900 and 1930 who smoked only cigarettes and kept smoking died on average about 10 years younger than men who had never smoked. Quitting gained years of life at every age, as Table 6.6 shows.
Table 6.6. Approximate years of life expectancy gained by stopping smoking at different ages, male British doctors, 1951 to 2001 (Doll et al., 2004).
| Age at stopping smoking | Years of life expectancy gained (approximate) |
|---|---|
| 30 | 10 |
| 40 | 9 |
| 50 | 6 |
| 60 | 3 |
Among men born around 1920, prolonged cigarette smoking from early adult life tripled death rates at each age, stopping at age 50 halved the excess risk, and stopping at age 30 avoided almost all of it (Doll et al., 2004). The two studies were central to establishing the harm of smoked tobacco and the benefit of stopping. The final part of this section turns to tobacco use in Canada today.
7.3 Tobacco in Canada Today
Smoking has declined in Canada over several decades, but it remains common, and in the 2020 estimates cited at the start of this section it was the leading cause of substance-related death. This part summarizes current figures and the legal framework that HSCI 402 develops in detail.
Survey estimates differ because surveys ask different questions of different age groups. In the Canadian Community Health Survey 2022, about 12 percent of people in Canada aged 12 and older smoked, down from 15 percent in 2019 (Health Canada, 2024b). In the Canadian Substance Use Survey 2023, which asked about any cigarette smoking in the past 30 days, 13 percent of respondents had smoked, including 14 percent of people aged 15 to 24 (Health Canada, 2024a). Tobacco use cost Canadian society about $11.2 billion in 2020 (Health Canada, 2024b).
These figures, and the laws described below, concern commercial tobacco, which the box below distinguishes from traditional tobacco.
Traditional tobacco and commercial tobacco
Lesson 2 described the ceremonial use of tobacco in many Indigenous cultures. The First Nations Health Authority (FNHA) in British Columbia explains that for thousands of years traditional tobacco has been part of many First Nations cultures in British Columbia and across Canada, that many Nations consider it a sacred plant with healing and spiritual benefits, and that it is often used for ceremony and prayer. The FNHA stresses that traditional tobacco and its sacred uses should not be confused with commercial tobacco, which it links to the high rates of dependence and health harms seen today (First Nations Health Authority, 2026). This section concerns commercial tobacco products: manufactured cigarettes and other products sold for recreational use.
Federal law treats commercial tobacco as a legal product with restrictions. The Tobacco and Vaping Products Act states its purpose as protecting the health of Canadians “in light of conclusive evidence implicating tobacco use in the incidence of numerous debilitating and fatal diseases,” and it prohibits furnishing tobacco or vaping products to anyone under 18 in a public place (Tobacco and Vaping Products Act, consolidation current to 30 September 2026); provinces add their own rules. Canada’s Tobacco Strategy, released in 2018, set a target of less than 5 percent tobacco use by 2035 (Health Canada, 2018). HSCI 402 develops tobacco regulation and treatment to help people stop smoking, including the medicines that act on nicotinic receptors.
Summary and Transition
Nicotine activates α4β2 nicotinic receptors and releases dopamine, and the cigarette delivers it to the brain within seconds, many times a day, in a pattern that keeps receptors desensitized and makes withdrawal a daily experience. Nicotine sustains the habit, while the toxins produced by burning tobacco cause most of the disease, as Doll and Hill’s case-control study and the 50-year British Doctors Study demonstrated. If combustion is the main source of harm, products that deliver nicotine without burning tobacco could reduce harm for people who would otherwise smoke, and they could also create new risks, especially for young people who have never smoked. Section 4 examines e-cigarettes, heated tobacco products and nicotine pouches, and the debate over tobacco harm reduction.
Key Takeaways
- 6.1 Nicotine is an agonist at nicotinic acetylcholine receptors, ion channels of five subunits that open to let sodium or calcium into the cell. A 2010 review by Benowitz identified the α4β2 receptor as the principal mediator of nicotine dependence: nicotine activates these receptors on neurons in the ventral tegmental area, which release dopamine in the nucleus accumbens, a pathway resembling the one on which cocaine and amphetamine act.
- 6.2 A cigarette delivers nicotine to the brain within 10 to 20 seconds and lets the person adjust the dose puff by puff, which produces rapid reinforcement. A half-life of about 2 hours invites the next dose, daily smoking keeps α4β2 receptors desensitized so that craving and withdrawal begin as levels fall, and conditioned cues tied to daily routines trigger urges to smoke. Together these features help explain why only about 3 percent of people who smoke in the United States quit successfully each year.
- 7.1 Smoking-caused disease comes from the toxins in tobacco smoke, while nicotine sustains the habit. Tobacco use is a known or probable cause of more than 40 diseases and can shorten life expectancy by about 10 years, whereas most nicotine replacement products deliver nicotine slowly without smoke and have low potential for problematic use.
- 7.2 Doll and Hill’s 1950 case-control study compared patients with lung cancer with hospital controls: only 2 of 649 men with lung cancer did not smoke, compared with 27 of 649 male controls, and heavy smoking was more common among the cases. The British Doctors Study, a cohort study followed for 50 years, found that men who kept smoking died about 10 years younger than men who never smoked, and that stopping at age 30 avoided almost all of the excess risk.
- 7.3 About 12 percent of people in Canada aged 12 and older smoked in 2022, down from 15 percent in 2019, and tobacco was responsible for 46,366 deaths in 2020, nearly two in three deaths attributed to substance use. These figures concern commercial tobacco, which the First Nations Health Authority distinguishes from traditional tobacco, a sacred plant used in ceremony and prayer. Canada’s Tobacco Strategy set a target of less than 5 percent tobacco use by 2035.
Reflection
Benowitz (2010) wrote that nicotine “plays a minor role, if any, in causing smoking-induced diseases,” but that “addiction to nicotine is the proximate cause of these diseases.” Explain this statement using three pieces of evidence from Section 3: (a) cigarettes deliver nicotine to the brain within 10 to 20 seconds and nicotine has a half-life of about 2 hours; (b) daily smoking keeps α4β2 receptors desensitized, and they recover during overnight abstinence; and (c) Doll and Hill’s 1950 case-control study and the British Doctors Study, in which men who kept smoking died about 10 years younger and stopping at age 30 avoided almost all of the excess risk.
Benowitz separates two roles. Nicotine is what people seek and what keeps them smoking, while the toxins produced by burning tobacco are what cause cancer, heart disease and lung disease. The statement means that nicotine is the reason the exposure continues for decades, and combustion is the reason the exposure is deadly.
The pharmacology explains why the habit is so persistent. A puff delivers nicotine to the brain within 10 to 20 seconds, faster than an injection, which gives strong and immediate reinforcement. With a half-life of about 2 hours, nicotine falls quickly enough that the next cigarette is soon wanted, and it accumulates through the day. Daily smoking keeps α4β2 receptors desensitized; overnight they recover, and the person wakes with craving and withdrawal that the first cigarette relieves. Cues tied to routines strengthen the cycle.
The epidemiology shows what this sustained exposure costs. Doll and Hill found that only 0.3 percent of men with lung cancer did not smoke, compared with 4.2 percent of controls, with a dose-response gradient. The British Doctors Study showed that men who kept smoking died about 10 years earlier, and that stopping at 30 avoided almost all of the excess risk. Since NRT delivers nicotine slowly and without smoke, the harm lies mainly in combustion, while addiction keeps people exposed to it.
Minimum 20 characters required.
Question 1: Which receptor does Benowitz (2010) identify as the principal mediator of nicotine dependence?
Question 2: Why do craving and withdrawal often begin in people who smoke during the night?
Question 3: In Doll and Hill’s (1950) study, 2 of 649 men with lung cancer and 27 of 649 male controls did not smoke. What do these figures show?
Question 4: Which statement best summarizes Benowitz’s (2010) view of nicotine’s role in smoking-caused disease?
E-cigarettes, Heated Tobacco, Nicotine Pouches and the Harm Reduction Debate
Introduction
Section 3 established that nicotine sustains smoking and that the products of burning tobacco cause most of the disease. This observation is the basis of tobacco harm reduction: the idea that death and disease among people who use nicotine could be reduced if those who would otherwise keep smoking switched completely to products that deliver nicotine without combustion. The idea is contested. Supporters point to the large difference in toxic exposure between smoking and the newer products. Critics worry about long-term risks that are not yet known, about people who use both products, and about young people who start using nicotine through the newer products and might move on to cigarettes.
The debate turns on three questions, which organize this section after a description of the products (8.1): how much less harmful the products are (8.2), whether they help adults stop smoking (8.3), and what they do to nicotine use among young people (8.4). The final part (9.1) weighs the evidence using a recent Canadian decision about nicotine pouches. HSCI 402 develops the regulation of these products.
Learning Objectives
- 8.1 Describe e-cigarettes, heated tobacco products and nicotine pouches, and their legal status in Canada as of 2026.
- 8.2 Place nicotine products on a continuum of risk, using the evidence reviewed by the National Academies (2018), and explain why the uncertainty around each product differs.
- 8.3 Summarize the evidence from the Cochrane living review of e-cigarettes for smoking cessation (Lindson et al., 2025), explain how the evidence changed since the National Academies review, and describe the conflicting positions of Canadian public health bodies.
- 8.4 Interpret survey evidence on vaping and smoking among young people in Canada, including Hammond and colleagues’ (2019) comparison of Canada, England and the United States.
- 9.1 Explain the logic of tobacco harm reduction and the three questions on which the debate turns, and weigh conflicting evidence and positions on a real Canadian policy decision about nicotine products.
8.1 Three Non-combustible Nicotine Products
The three products discussed here deliver nicotine without burning tobacco, and they differ in what they contain, how they are regulated and how much is known about them.
8.1.1 E-cigarettes
E-cigarettes (also called vapes or electronic cigarettes) are handheld electronic devices that produce an aerosol by heating a liquid, which the user inhales (Lindson et al., 2025). The liquid usually contains nicotine and flavourings. Some products use nicotine salts, which produce a vapour that reduces the harshness of high nicotine concentrations in the throat; Hammond and colleagues (2019) describe JUUL, whose use increased among adolescents in all three countries they studied in 2018, as a nicotine salt product with a high nicotine concentration. In Canada, the Tobacco and Vaping Products Act made nicotine vaping products legal for adults in 2018 “as a less harmful option than smoking” (Health Canada, 2018), and since 8 July 2021 federal regulations have limited the nicotine concentration of vaping liquids to 20 mg/mL, a limit unchanged in the consolidation current to 19 October 2026 (Nicotine Concentration in Vaping Products Regulations, 2021).
8.1.2 Heated Tobacco Products
Heated tobacco products heat tobacco leaf or sheet to a temperature high enough to release an aerosol without burning it or producing smoke; they differ from e-cigarettes because they heat tobacco itself (Tattan-Birch et al., 2022). Because they contain tobacco, they meet the definition of a tobacco product under the Tobacco and Vaping Products Act, which, in its consolidation current to 30 September 2026, prohibits promoting a tobacco product in a manner that could cause a person to believe that it or its emissions are less harmful than other tobacco products (Tobacco and Vaping Products Act, 2026).
8.1.3 Nicotine Pouches
Nicotine pouches are small tobacco-free pouches held in the mouth, where nicotine is absorbed. Travis and colleagues (2026), in a scoping review, report that their use has risen in the United States and worldwide and that higher-strength pouches (6 mg or more) typically deliver more nicotine than a cigarette to adults who smoke. In Canada, according to a Health Canada advisory last updated in August 2025, nicotine pouches are authorized only as nicotine replacement therapy to help adults stop smoking, must carry a Natural Product Number (NPN) on the label, and no authorized pouch contains more than 4 mg of nicotine per dose (Health Canada, 2025c).
Table 6.7 summarizes the three products alongside conventional nicotine replacement therapy (NRT), which Section 3 described.
Table 6.7. Non-combustible nicotine products compared by what they contain, their status in Canada as of 2026, and the main evidence reviewed in this section.
| Product | What it contains or heats | Status in Canada (2026) | Main evidence in this section |
|---|---|---|---|
| E-cigarette | Heats a liquid, usually with nicotine and flavourings | Legal for adults since 2018; nicotine limited to 20 mg/mL since 2021 | NASEM (2018); Lindson et al. (2025) |
| Heated tobacco product | Heats tobacco without burning it | Regulated as a tobacco product; relative-harm promotion prohibited | Tattan-Birch et al. (2022) |
| Nicotine pouch | Tobacco-free pouch held in the mouth | Authorized only as NRT for adults; sold by pharmacists since 2024 | Heshmati et al. (2025); Travis et al. (2026) |
| Nicotine replacement therapy | Patches, gum, lozenges, sprays, inhalers | Regulated as drugs; widely available | Benowitz et al. (2009) |
With the products described, the next part takes up the first question in the debate: how their risks compare with smoking.
8.2 Relative Risk: How Much Less Harmful
The reviews and agencies cited in this section agree that switching completely from cigarettes to e-cigarettes reduces exposure to toxicants (NASEM, 2018; Health Canada, 2026). The disagreement concerns how much less harmful the products are, how the products differ from one another, and how certain anyone can be.
8.2.1 What the National Academies Concluded
In 2018, the United States National Academies of Sciences, Engineering, and Medicine (NASEM) published a review of the health effects of e-cigarettes. The committee rated each conclusion by the strength of the evidence behind it, using the categories in the box below. Lesson 7 uses a similar scheme from a NASEM review of cannabis.
NASEM levels of evidence and selected conclusions on e-cigarettes (2018)
Conclusive: many supportive findings from good-quality controlled studies with no credible opposing findings. Substantial: several supportive findings from good-quality observational studies or controlled trials with few or no credible opposing findings. Moderate: several supportive findings from fair-quality studies. Limited: supportive findings from fair-quality studies, or mixed findings, with significant uncertainty remaining.
Insufficient: too few studies, or studies of too low a quality, to support or refute a conclusion.
- Conclusive evidence that completely substituting e-cigarettes for combustible tobacco cigarettes reduces users’ exposure to numerous toxicants and carcinogens present in cigarettes.
- Substantial evidence that e-cigarette use results in symptoms of dependence on e-cigarettes, and moderate evidence that the risk and severity of dependence are lower than for cigarettes.
- Conclusive evidence that e-cigarette devices can explode and cause burns, and that drinking or injecting e-liquids, intentionally or by accident, can be fatal.
The first conclusion in the box above concerns exposure to toxicants, measured with biological markers in the blood and urine. Lower exposure is expected to mean less disease, but smoking-related disease can take decades to appear (Section 3), so evidence on the long-term health effects of vaping is still accumulating. Health Canada (2026) puts the position this way: “switching completely to vaping is less harmful than continuing to smoke, it’s not harmless and isn’t intended for young people.” It adds that vaping may cause lung damage by exposing people to harmful chemicals such as formaldehyde and acrolein, and that more research is needed to establish the health risks of long-term vaping.
8.2.2 Heated Tobacco and Nicotine Pouches
The evidence on heated tobacco is thinner. Tattan-Birch and colleagues (2022), in a Cochrane review, found 11 randomized trials of safety with 2,666 participants. All were funded by tobacco companies and the median follow-up was 13 weeks. There was moderate-certainty evidence that people who switched to heated tobacco had lower levels of two markers of toxic exposure than people who kept smoking, and, with less certainty, higher levels than people attempting to stop using tobacco altogether. A later systematic review by Braznell and colleagues (2026), with searches to December 2024, found that only nine of its 40 studies lasted longer than five days and that short-term effects on biomarkers of potential harm were mixed, and its authors concluded that the data did not yet give a clear indication of harm or benefit, even compared with cigarettes. Evidence on heated tobacco is therefore still early and evolving. For nicotine pouches, Travis and colleagues (2026) concluded that pouches are considerably less toxic than cigarettes, but that their long-term health effects remain understudied. Lindson and colleagues (2025) add a further caution: the trials they reviewed tested regulated nicotine e-cigarettes, and illegal products or products containing other substances, such as tetrahydrocannabinol (THC), may have different harms.
Interactive 6.2 asks you to place each product on a continuum running from the lowest-risk end to the combustible cigarette, and then to compare your placement with an illustrative summary of the evidence.
Move each slider to where you think the product sits, from the lowest-risk end (left) to the combustible cigarette (right), then select Compare with the evidence.
The shaded ranges are illustrative summaries written for this lesson to show the likely order of the products and how uncertain each position is. They are not measured values, and none of the sources cited assigns these numbers.
The widths of the ranges in Interactive 6.2 matter as much as their positions: narrow where evidence is long-standing, wide where it is short-term or industry funded. The second question is whether the products help people who smoke to stop.
8.3 Adult Switching: Evidence on Stopping Smoking
A lower-risk product reduces harm only if people who smoke switch to it completely. The best evidence on switching comes from randomized controlled trials, in which people who smoke are assigned by chance to receive an e-cigarette or another treatment.
8.3.1 The Cochrane Living Review
Cochrane reviews are systematic reviews that follow standard methods and rate the certainty of their evidence. The review of e-cigarettes for smoking cessation is a living systematic review: its authors search for new studies every month and update the review when new evidence appears. The update by Lindson and colleagues published in November 2025 included 104 studies with 30,366 participants, 61 of them randomized trials. Its main findings were these:
- High-certainty evidence that nicotine e-cigarettes increase quit rates compared with NRT (risk ratio 1.55, 95 percent confidence interval 1.28 to 1.88; 9 trials, 2,703 participants), about three additional people stopping smoking for every 100.
- Moderate-certainty evidence of higher quit rates compared with e-cigarettes without nicotine (risk ratio 1.34), and low-certainty evidence compared with behavioural support alone or no support (risk ratio 1.78).
- No evidence of serious harm, with throat and mouth irritation, headache, cough and nausea the most common side effects, and a need for longer and larger trials of safety.
A risk ratio compares the proportion of people with an outcome in two groups: a risk ratio of 1.55 means that people given e-cigarettes were about 1.55 times as likely to have stopped smoking for at least six months as people given NRT. The earlier update published in January 2025 had found a similar result from fewer trials (risk ratio 1.59; Lindson et al., 2025). A further update published in August 2026, which included only randomized trials (80 trials, 29,861 participants), again found high-certainty evidence of higher quit rates with nicotine e-cigarettes than with NRT (risk ratio 1.61, 95 percent confidence interval 1.23 to 2.12; 11 trials, 4,114 participants), about four additional people stopping for every 100 (Lindson et al., 2026). The estimate has held fairly steady as evidence accumulated, although, because the review is updated as trials appear, it may change again.
The evidence has changed considerably since 2018, when NASEM found only limited evidence that e-cigarettes may help people stop smoking and insufficient evidence to compare them with approved treatments. This change illustrates how a scientific judgement depends on the evidence available at a given date.
8.3.2 The Other Products, and Dual Use
For heated tobacco, the 2022 Cochrane review, with searches to January 2021, found no trial that measured whether people stopped smoking, so its authors judged the effectiveness of heated tobacco for this purpose uncertain (Tattan-Birch et al., 2022). For nicotine pouches, Heshmati and colleagues (2025) reviewed seven small randomized trials with 269 participants. Pouches were well tolerated and in one pilot trial reduced daily cigarette use from 15.0 to 8.3 cigarettes over eight weeks, but no trial showed a statistically significant increase in quitting. A Cochrane review published in October 2025 by Hartmann-Boyce and colleagues (2025), which included four small trials with 284 participants, likewise judged the evidence on pouches for quitting smoking limited and very uncertain. Travis and colleagues (2026) report that pouch use by daily smokers generally results in dual use, the use of both products, more often than complete cessation.
8.3.3 Conflicting Canadian Positions
Canadian public health bodies have read this evidence differently. Canada’s Tobacco Strategy (Health Canada, 2018) describes access to less harmful products for people who smoke as a way to reduce their health risks. In January 2025, the Council of Chief Medical Officers of Health stated that approved smoking cessation methods do not at present include nicotine vaping products, encouraged manufacturers to seek approval of their products as cessation aids, and recommended that all flavoured nicotine vaping products be banned, as several provinces and territories had already done (Council of Chief Medical Officers of Health, 2025). Their concern for young people is the subject of the next part.
8.4 Youth Uptake
The third question concerns young people. A product that helps adults stop smoking could still cause harm overall if it leads many young people who would never have smoked to use nicotine.
8.4.1 A Three-country Comparison
Hammond and colleagues (2019) surveyed national samples of 16 to 19 year olds in Canada, England and the United States in 2017 and 2018, using repeated cross-sectional online surveys, which draw a new sample at each round. Table 6.8 shows their main results for vaping in the past 30 days, both as first published and as the authors later re-estimated them.
Table 6.8. Percentage of 16 to 19 year olds who vaped in the past 30 days in Canada, England and the United States, 2017 and 2018, as first published (Hammond et al., 2019, Table 2) and as re-estimated with revised survey weights (Hammond, Rynard and Reid, 2020).
| Estimate | Canada 2017 | Canada 2018 | England 2017 | England 2018 | United States 2017 | United States 2018 |
|---|---|---|---|---|---|---|
| First published (2019) | 8.4 | 14.6 | 8.7 | 8.9 | 11.1 | 16.2 |
| Revised weights (2020) | 8.4 | 12.1 | 8.7 | 9.0 | 11.1 | 15.7 |
In the first published estimates, vaping rose sharply in Canada and the United States between 2017 and 2018, including among young people who had never smoked, with no change in England. The authors judged changes in the product market, especially the spread of nicotine salt products, the most plausible explanation. In England, European Union rules limited e-liquids to 20 mg/mL of nicotine, so JUUL pods there contained less than half the nicotine of Canadian and United States products, which could explain why vaping did not rise; Canada adopted the same limit in 2021. The 2019 paper also reported a rise in past-30-day smoking in Canada (10.7 to 15.5 percent). The authors later updated their estimates (Hammond, Rynard and Reid, 2020), weighting each survey so that its smoking trend matches national surveillance surveys. With these weights, vaping in Canada still rose, more modestly (8.4 percent in 2017, 12.1 percent in 2018 and 17.8 percent in 2019), and smoking among Canadian 16 to 19 year olds declined very slowly between 2017 and 2024 (Hammond et al., 2026).
8.4.2 Canadian Trends Since 2018
Canadian surveys from 2023 and 2024 show that vaping among young people was still common. In the Canadian Student Alcohol and Drugs Survey (CSADS, 2023 to 2024), 15 percent of students in grades 7 to 12 in nine provinces had vaped in the past 30 days, compared with 4 percent who had smoked a cigarette (Health Canada, 2025a). In the Canadian Substance Use Survey 2023, 28 percent of people aged 15 to 24 had vaped in the past 30 days (Health Canada, 2024a). In June 2024, Health Canada described youth vaping rates as having levelled off since 2021 while remaining high, and identified flavours as a major contributor to the earlier rapid rise (Health Canada, 2024b).
8.4.3 Vaping and Later Smoking
NASEM (2018) found substantial evidence that e-cigarette use increases the risk of ever using cigarettes among youth and young adults. Because young people cannot ethically be assigned to vape, this evidence is observational, and other differences between young people who vape and those who do not cannot be completely ruled out. A 2021 meta-analysis by Chan and colleagues (2021) found a longitudinal association between adolescent vaping and later smoking, but judged the evidence limited by publication bias, high attrition and inadequate adjustment for shared risk factors, so whether vaping causes later smoking remains debated. Population trends are harder to read. Smoking among people in Canada aged 12 and older fell from 15 percent in 2019 to 12 percent in 2022 (Health Canada, 2024b), during years of high youth vaping, but a trend of this kind cannot show what would have happened without vaping. The purposes of the Tobacco and Vaping Products Act reflect this concern: for vaping products, the Act aims to prevent their use from leading to tobacco use by young persons and by people who do not use tobacco.
Interactive 6.3 asks you to match seven claims from the debate with the evidence that bears on each.
For each claim, choose the evidence that bears most directly on it, then select Check my matches. The feedback also says how well the evidence supports the claim.
Matching claims to evidence shows that participants in the debate often make different kinds of claims, supported by different kinds of studies. The final part brings the three questions together.
9.1 Weighing the Debate
Weighing tobacco harm reduction means considering adults who smoke and young people who do not at the same time, under uncertainty that differs by product. Case 6.2 describes a Canadian decision in which these considerations met.
Health Canada authorized its first nicotine pouch for adults trying to stop smoking in 2023 (Health Canada, 2025d); the Canadian Press identified it as Zonnic. As nicotine replacement therapy, it was at first sold without age restrictions, and in 2024 the federal health minister said the pouches were reaching young people (Osman, 2024). On 22 August 2024, Health Canada announced a ministerial order, in effect from 28 August 2024 (Health Canada, 2025c), under which new forms of NRT such as nicotine pouches may be sold only by a pharmacist or under a pharmacist’s supervision, kept behind the pharmacy counter, sold only in mint or menthol flavours, labelled with a front-of-package warning about nicotine addiction, and not promoted in ways that could appeal to youth (Health Canada, 2024c). Gums, lozenges, sprays and inhalers remained widely available in stores.
Health Canada pointed to the United States National Youth Tobacco Survey of 2023, in which nicotine pouches were among the more popular tobacco and nicotine products among middle and high school students (Health Canada, 2024c). Travis and colleagues (2026) later reported current pouch use of 1.8 percent among United States middle and high school students in 2024. As of September 2026, the restrictions remained in place: the federal health minister said she was not considering loosening them, while unauthorized pouches were reported to be sold illegally online and in stores (Ritchie, 2026).
The three tabs below set out the strongest evidence on each side and the evidence that could change the balance, drawing only on the sources in this section.
Combustion causes most smoking-related disease (Section 3). Completely switching to e-cigarettes reduces exposure to numerous toxicants and carcinogens (NASEM, 2018, conclusive evidence). Nicotine e-cigarettes help more people stop smoking than NRT (Lindson et al., 2025, 2026, high-certainty evidence). Health Canada (2026) states that switching completely to vaping is less harmful than continuing to smoke.
Health Canada (2026) states that more research is needed to establish the health risks of long-term vaping. E-cigarettes produce dependence (NASEM, 2018), and youth vaping rose in Canada between 2017 and 2018 (Hammond et al., 2019; Hammond, Rynard and Reid, 2020) and was still common in 2023 to 2024 (Health Canada, 2025a). E-cigarette use is associated with later cigarette use among young people (NASEM, 2018, substantial evidence), although whether the link is causal is debated (Chan et al., 2021). The heated tobacco trials in a 2022 review were short-term and industry funded (Tattan-Birch et al., 2022), and the small pouch trials reviewed in 2025 did not show that pouches increase quitting (Heshmati et al., 2025; Hartmann-Boyce et al., 2025).
Longer and larger trials of safety (Lindson et al., 2025), independently funded studies of heated tobacco (Tattan-Birch et al., 2022), trials of nicotine pouches that measure quitting (Heshmati et al., 2025), and studies of health outcomes in long-term users (Travis et al., 2026) would each narrow the uncertainty ranges in Interactive 6.2. Better evidence on whether youth vaping causes later smoking would sharpen the youth side of the debate.
Weighing the debate well means stating which population a claim concerns, what kind of study supports it, and how certain that evidence is. Try it 6.4 applies this approach to Case 6.2.
Prepare a short evidence brief on Health Canada’s August 2024 order on nicotine pouches (Case 6.2). In your brief, (1) place authorized nicotine pouches on the continuum from Interactive 6.2 and explain the width of your uncertainty range; (2) use Section 3 to explain why a pouch delivers nicotine more slowly than a cigarette and why that matters for dependence; (3) state the strongest piece of evidence for and against restricting pouches to pharmacies, naming the population each concerns; and (4) name one study that, if it were done, would most change your view. Compare your brief with the tabs above.
Summary
E-cigarettes, heated tobacco products and nicotine pouches deliver nicotine without burning tobacco. The evidence that they reduce exposure to toxicants, compared with smoking, is strong for e-cigarettes and weaker and more recent for the other two, and evidence on their long-term risks is still accumulating. In the 2025 and 2026 updates of the Cochrane living review, high-certainty trial evidence showed that nicotine e-cigarettes help more adults stop smoking than NRT, while the reviews of heated tobacco (2022) and of nicotine pouches (2025) found no trial evidence that these products increase quitting. Youth vaping in Canada rose after 2017 and was still common in 2023 to 2024, and observational evidence links it with later smoking, although whether vaping causes later smoking is debated. These findings support different conclusions depending on which population is placed first. The reflection and final assessment that follow draw on all four sections of the lesson.
Key Takeaways
- 8.1 E-cigarettes heat a liquid that usually contains nicotine and flavourings, heated tobacco products heat tobacco without burning it, and nicotine pouches are tobacco-free pouches held in the mouth. In Canada as of 2026, nicotine vaping products have been legal for adults since 2018, with nicotine limited to 20 mg/mL since 2021; heated tobacco is regulated as a tobacco product that may not be promoted as less harmful; and nicotine pouches are authorized only as nicotine replacement therapy for adults, at no more than 4 mg per dose.
- 8.2 NASEM (2018) found conclusive evidence that completely substituting e-cigarettes for cigarettes reduces exposure to numerous toxicants and carcinogens, and evidence on the long-term health effects of vaping is still accumulating. The heated tobacco trials in a 2022 review were short and industry funded, and a 2026 review described the long-term effects of pouches as understudied. On a continuum of risk, the uncertainty is narrow where evidence is long-standing and wide where it is short-term or industry funded.
- 8.3 The November 2025 update of the Cochrane living review found high-certainty evidence that nicotine e-cigarettes increase quit rates compared with NRT (risk ratio 1.55), about three additional people stopping for every 100, a marked change from the limited evidence NASEM found in 2018. The studies described here include no trial showing that heated tobacco or nicotine pouches increase quitting, and pouch use often leads to dual use. Canadian bodies read this evidence differently: the Tobacco Strategy treats access to less harmful products as a way to reduce risk, while the Council of Chief Medical Officers of Health notes that approved cessation methods do not include vaping products and recommends banning flavoured vaping products.
- 8.4 Hammond and colleagues (2019) found that past-30-day vaping among 16 to 19 year olds rose sharply in Canada and the United States between 2017 and 2018 but not in England, where nicotine in e-liquids was limited to 20 mg/mL; revised survey weights showed a more modest Canadian rise (8.4 to 12.1 percent). Vaping among young people in Canada was still common, at 15 percent of students in grades 7 to 12 in 2023 to 2024, and NASEM found substantial, though observational, evidence that e-cigarette use increases the risk of later cigarette use, although whether the link is causal is debated.
- 9.1 Tobacco harm reduction holds that death and disease could be reduced if people who would otherwise keep smoking switched completely to products that deliver nicotine without combustion, and the debate turns on relative risk, adult switching and youth uptake. Health Canada’s 2024 order restricting nicotine pouches to sale by or under the supervision of a pharmacist (Case 6.2) shows how the interests of adults who smoke and young people who do not must be weighed together. Weighing the debate well means stating which population a claim concerns, what kind of study supports it and how certain that evidence is.
Reflection
Two Canadian positions on vaping appear in Section 4. Health Canada states that switching completely to vaping is less harmful than continuing to smoke, although vaping is not harmless, and Canada’s Tobacco Strategy (2018) describes less harmful products as a way to reduce health risks for people who smoke. In January 2025, the Council of Chief Medical Officers of Health stated that approved smoking cessation methods do not at present include nicotine vaping products and recommended banning flavoured vaping products. Meanwhile, the November 2025 Cochrane review found high-certainty evidence that nicotine e-cigarettes increase quit rates compared with nicotine replacement therapy (risk ratio 1.55), and the Canadian Student Alcohol and Drugs Survey (2023 to 2024) found that 15 percent of students in nine provinces had vaped in the past 30 days, compared with 4 percent who had smoked. Explain how both positions can be grounded in evidence, and identify the additional evidence that would most help resolve the disagreement.
Both positions start from real evidence but give priority to different populations. Health Canada’s position focuses on adults who already smoke. For them the relevant comparison is with continued smoking, and the evidence is strong: NASEM rated the reduction in toxicant exposure from complete switching as conclusive, and the Cochrane review found high-certainty evidence that nicotine e-cigarettes help more people stop smoking than NRT, about three more per 100.
The chief medical officers focus more on young people and on the formal approval of cessation aids. For a young person who has never smoked, the comparison is with not using nicotine at all, and vaping then adds dependence and long-term risks that are still being studied. Youth vaping was common in the 2023 to 2024 student survey, at 15 percent of students compared with 4 percent who smoked, and NASEM found substantial observational evidence that vaping increases the risk of later smoking, although a 2021 meta-analysis judged that shared risk factors were poorly controlled, so whether the link is causal is debated. From this angle, flavour bans and medical approval routes make sense even if vaping is less harmful than smoking for adults.
The evidence that would most help is longer-term: cohort studies of disease in long-term vapers, trials that track complete switching and dual use beyond a year, and studies that can separate a causal effect of vaping on youth smoking from shared risk factors. Evidence on whether pharmacy-only or prescription routes reach adults who smoke would also inform the debate.
Minimum 20 characters required.
Question 1: Which conclusion did NASEM (2018) rate as supported by conclusive evidence?
Question 2: In the November 2025 Cochrane living review, nicotine e-cigarettes compared with NRT had a risk ratio for quitting of 1.55. What does this mean?
Question 3: Why is the uncertainty about the relative risk of heated tobacco products wider than for e-cigarettes?
Question 4: Hammond and colleagues (2019) found that vaping among 16 to 19 year olds rose between 2017 and 2018 in Canada and the United States but not in England. Which explanation did they consider most plausible?
Final Assessment
Bringing It All Together
This lesson followed the stimulants from the transporter to the population. Cocaine blocks the dopamine and noradrenaline transporters, and amphetamine and methamphetamine reverse them; ADHD medicines use the same mechanisms at oral, therapeutic doses, and caffeine works indirectly by blocking adenosine receptors. Nicotine activates α4β2 nicotinic receptors. Across all of these drugs, the speed with which a route delivers the drug to the brain shaped how strongly it reinforces use, and the half-life shaped how long each dose acts.
The harms followed from both the drug and its setting. Stimulants raise heart rate and blood pressure, heavy methamphetamine use raises the odds of psychosis in a dose-dependent way, and in preliminary data for 2025 and 2026, stimulants were detected in a majority of the unregulated drug deaths in British Columbia that underwent expedited toxicology testing. Smoked tobacco was the largest single cause of substance-related death in Canada in the 2020 estimates, and the evidence from Doll and Hill onward shows that combustion, sustained by nicotine dependence, causes most of that harm.
The final section turned this finding into a debate. Complete switching to e-cigarettes reduces exposure to toxicants, and in the Cochrane living review nicotine e-cigarettes helped more adults stop smoking than nicotine replacement therapy, while youth vaping was still common in 2023 to 2024 and evidence on long-term risks is still accumulating. Canadian bodies have weighed the same evidence differently, which shows why it matters to state which population a claim concerns and how certain the evidence is.
Key Takeaways from this lesson
- Cocaine is a natural product sold as powder or crack, while amphetamine and methamphetamine are synthetic; all three are in Schedule I in Canada as of 2026, and methamphetamine’s half-life of about 9 hours keeps it acting far longer than cocaine.
- Cocaine is a transporter blocker, while amphetamine and methamphetamine are releasers that make the transporter pump dopamine out of the cell. Fast routes such as smoking and injection deliver stimulants to the brain within seconds to minutes and increase their reinforcing effects and risks.
- Reviews link stimulant use with cardiovascular disease, stroke, psychosis and elevated mortality, and a 2013 within-person study found a dose-response relationship between methamphetamine use and psychotic symptoms. In British Columbia in 2025, cocaine and methamphetamine were each detected in about half of unregulated drug deaths that underwent expedited toxicology testing.
- ADHD medicines use the same mechanisms as illegal stimulants, and slow-release and prodrug formulations reduce their potential for non-medical use. In meta-analyses published in 2015 and 2020, non-medical use of prescription stimulants was common among college students, and the cognitive benefit for healthy users was small or modest.
- Caffeine blocks adenosine receptors, produces tolerance and withdrawal, and has a half-life of about 2 to 8 hours in adults that smoking shortens and pregnancy lengthens; the half-life formula gives the amount remaining at any time after a dose.
- Nicotine dependence develops quickly because cigarettes deliver nicotine to the brain within 10 to 20 seconds and α4β2 receptors signal withdrawal as nicotine levels fall.
- Combustion, sustained by nicotine dependence, causes most smoking-related disease, as Doll and Hill’s case-control study and the British Doctors Study helped to establish, and stopping smoking early avoids most of the excess risk. Smoked tobacco was the largest single cause of substance-related death in Canada in the 2020 estimates.
- The certainty of evidence differs across e-cigarettes, heated tobacco and nicotine pouches: completely switching to e-cigarettes reduces toxicant exposure and, in the Cochrane living review, nicotine e-cigarettes helped more adults stop smoking than NRT, while evidence on the other products is thinner and youth vaping in Canada was still common in 2023 to 2024.
- The tobacco harm reduction debate turns on relative risk, adult switching and youth uptake, and weighing it means stating which population a claim concerns, what kind of study supports it and how certain the evidence is.
Core Concepts Reviewed
Section 1: stimulants, monoamines, the dopamine transporter, transporter blockers and releasers, reverse transport, cardiovascular harms, stimulant psychosis, dose-response relationships and stimulants in the unregulated drug supply.
Section 2: ADHD medicines, prodrugs and lisdexamfetamine, non-medical use of prescription stimulants, adenosine antagonism, caffeine tolerance and withdrawal, and the half-life calculation.
Section 3: nicotinic acetylcholine receptors, the α4β2 receptor, desensitization and upregulation, cotinine and CYP2A6, combustion, case-control and cohort studies, and traditional and commercial tobacco.
Section 4: e-cigarettes, nicotine salts, heated tobacco products, nicotine pouches, tobacco harm reduction, levels of evidence, living systematic reviews, risk ratios, dual use and youth uptake.
The final reflection asks you to compare two substances from the lesson and explain why related pharmacology can produce very different risks.
Reflection
Choose two of the following: cocaine, methylphenidate, caffeine, nicotine delivered by cigarettes, and nicotine delivered by e-cigarettes. For each, describe (a) its main mechanism of action, (b) how quickly it reaches the brain by its usual route, (c) its main harms according to the evidence in this lesson, and (d) its legal status in Canada as of 2026. Then explain, using your two examples, why substances with related pharmacology can carry very different risks to individuals and to populations.
I chose cocaine and nicotine delivered by cigarettes. Cocaine binds to the dopamine transporter and blocks the removal of dopamine and noradrenaline from the synapse. Smoked as crack or snorted as powder, it reaches the brain very quickly, and its half-life is about 0.7 to 1.5 hours. Its harms include heart attack, arrhythmias, stroke, psychosis with heavy use and a standardized mortality ratio of about six, and in British Columbia it was detected in about half of 2025 unregulated drug deaths with expedited testing. As of 2026, it is in Schedule I of the Controlled Drugs and Substances Act.
Nicotine activates α4β2 nicotinic receptors, which release dopamine. A cigarette delivers it to the brain within 10 to 20 seconds. Nicotine itself plays a minor role in disease, but tobacco use is a known or probable cause of more than 40 diseases, smoking can shorten life by about 10 years, and tobacco accounted for 46,366 deaths in Canada in 2020. As of 2026, cigarettes are legal for adults under the Tobacco and Vaping Products Act, which prohibits furnishing them to people under 18.
Both drugs raise dopamine and are delivered rapidly by smoking, which explains their strong reinforcement. Their risks differ because of what accompanies the drug. Cocaine’s acute toxicity and the unpredictable unregulated supply make each episode of use dangerous, while nicotine’s harm comes slowly from combustion, multiplied across millions of legal users over decades. Mechanism sets the potential for reinforcement; dose, route, product, supply and legal setting determine the harm.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: Which pairing of a drug with its main mechanism of action is correct?
Question 2: Which principle explains both why smoked crack is more reinforcing than oral amphetamine taken as prescribed and why a nicotine patch has lower potential for problematic use than a cigarette?
Question 3: Nicotine has a plasma half-life of about 2 hours. Which observation in the lesson follows from this?
Question 4: Which statement about liver enzymes and stimulants is supported by the lesson?
Question 5: Which pair correctly names the study designs used by Doll and Hill (1950) and by McKetin and colleagues (2013)?
Question 6: Which pair of findings are both examples of a dose-response relationship?
Question 7: Which claim in this lesson rests on high-certainty evidence from randomized controlled trials?
Question 8: The BC Coroners Service reported that cocaine was detected in 53 percent of 2025 deaths that underwent expedited toxicology testing. What does this figure show on its own?
Question 9: Under the Controlled Drugs and Substances Act (consolidation current to September 2026), which statement is accurate?
Question 10: Ferré (2016) suggests that part of the alertness regular coffee drinkers feel after a dose reflects which process?
Question 11: How does the First Nations Health Authority distinguish traditional tobacco from commercial tobacco?
Question 12: Canada adopted a 20 mg/mL limit on nicotine in vaping liquids in 2021. Which finding from Hammond and colleagues (2019) is relevant to that decision?
Question 13: Which feature of the evidence most widens the uncertainty about how harmful a nicotine product is compared with smoking?
Question 14: A health authority is deciding whether to restrict nicotine pouches to pharmacies. Which combination of evidence from this lesson is most relevant?
Question 15: Which statement about stimulant psychosis is supported by Farrell and colleagues (2019)?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
This glossary defines the terms, frameworks and people introduced in Lesson 6; use the search box to find a term quickly.